Purple Biotech PPBT Stock
Purple Biotech Price Chart
Purple Biotech PPBT Financial and Trading Overview
| Purple Biotech stock price | 1.77 USD |
| Previous Close | 1.7 USD |
| Open | 1.8 USD |
| Bid | 1.57 USD x 500 |
| Ask | 5.21 USD x 100 |
| Day's Range | 1.72 - 1.8 USD |
| 52 Week Range | 1.42 - 29 USD |
| Volume | 39.13K USD |
| Avg. Volume | 301.25K USD |
| Market Cap | 1.65M USD |
| Beta (5Y Monthly) | -0.543 |
| PE Ratio (TTM) | 0.0005486671 |
| EPS (TTM) | 3226 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30 USD |
PPBT Valuation Measures
| Enterprise Value | -4717849 USD |
| Trailing P/E | 0.0005486671 |
| Forward P/E | -2.0113637 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.177 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.605 |
Trading Information
Purple Biotech Stock Price History
| Beta (5Y Monthly) | -0.543 |
| 52-Week Change | -92.67% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 29 USD |
| 52 Week Low | 1.42 USD |
| 50-Day Moving Average | 3.48 USD |
| 200-Day Moving Average | 5.53 USD |
PPBT Share Statistics
| Avg. Volume (3 month) | 301.25K USD |
| Avg. Daily Volume (10-Days) | 1.16M USD |
| Shares Outstanding | 932.27K |
| Float | 925.48K |
| Short Ratio | 0.16 |
| % Held by Insiders | 3.73% |
| % Held by Institutions | 6.55% |
| Shares Short | 49.07K |
| Short % of Float | 5.26% |
| Short % of Shares Outstanding | 5.26% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -19.54% |
| Return on Equity (ttm) | -123.34% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -59000 USD |
| EBITDA | -7798000 USD |
| Net Income Avi to Common (ttm) | -26019000 USD |
| Diluted EPS (ttm) | 3226 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 6.43M USD |
| Total Cash Per Share (mrq) | 6.91 USD |
| Total Debt (mrq) | 184K USD |
| Total Debt/Equity (mrq) | 1.9 USD |
| Current Ratio (mrq) | 1.476 |
| Book Value Per Share (mrq) | 10 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -6799000 USD |
| Levered Free Cash Flow (ttm) | -2496125 USD |
Profile of Purple Biotech
| Country | United States |
| State | N/A |
| City | Rehovot |
| Address | 4 Oppenheimer Street |
| ZIP | 7670104 |
| Phone | 972 3 933 3121 |
| Website | https://purple-biotech.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 10 |
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company was incorporated in 1968 and is headquartered in Rehovot, Israel.
Q&A For Purple Biotech Stock
What is a current PPBT stock price?
Purple Biotech PPBT stock price today per share is 1.77 USD.
How to purchase Purple Biotech stock?
You can buy PPBT shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Purple Biotech?
The stock symbol or ticker of Purple Biotech is PPBT.
Which industry does the Purple Biotech company belong to?
The Purple Biotech industry is Biotechnology.
How many shares does Purple Biotech have in circulation?
The max supply of Purple Biotech shares is 932.27K.
What is Purple Biotech Price to Earnings Ratio (PE Ratio)?
Purple Biotech PE Ratio is 0.00054867 now.
What was Purple Biotech earnings per share over the trailing 12 months (TTM)?
Purple Biotech EPS is 3226 USD over the trailing 12 months.
Which sector does the Purple Biotech company belong to?
The Purple Biotech sector is Healthcare.
Purple Biotech PPBT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
- {{ link.label }} {{link}}